Document is current
Any future updates will be listed below
-
Authors
Zhou, Katherine I.
Strickler, John H.
Chen, Hui
- License Information
-
More Information
Article History
Received: 9 July 2024
Accepted: 9 August 2024
First Online: 26 August 2024
Declarations
:
: This is not applicable for this summary.
: This is not applicable for this summary.
: John Strickler is currently, or has recently been a consultant or advisor for Abbvie, Astellas, AstraZeneca, Bayer, Beigene, Daiichi-Sankyo, Eli Lilly, GE Healthcare, GSK, Johnson and Johnson, Jazz Pharmaceuticals, Merck, Natera, Pfizer, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, Xilio Therapeutics. He has stock options in Triumvira Immunologics. He has also received recent research funding from or conducted contracted research with Abbvie, Amgen, AStar D3, Bayer, Beigene, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, Roche/ Genentech.
